Diamyd Medical expands activities to both type 1 and type 2 diabetes as well as rheumatoid arthritis with proprietary GABA drug
09 sept. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that the Company will expand its activities to include both type 1 and type 2
diabetes as well as rheumatoid arthritis,...
Diamyd Medical breddar verksamheten mot både typ 1- och typ 2-diabetes samt reumatoid artrit med eget GABA-läkemedel
09 sept. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag att Bolaget
breddar verksamheten till att omfatta både typ 1- och typ 2-diabetes samt
reumatoid artrit, vilken planeras drivas genom...
Diamyd Medical provides update on clinical studies with Diamyd®
07 sept. 2016 06h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq First North, Stockholm, DMYD B) participates in six
clinical studies with the diabetes vaccine Diamyd® for the treatment and
prevention of type 1 diabetes. The Company announced...
Diamyd Medical ger uppdatering om kliniska studier med Diamyd®
07 sept. 2016 06h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) deltar i sex kliniska
studier med diabetesvaccinet Diamyd® för behandling och prevention av typ 1
-diabetes. Bolaget meddelar idag att ytterligare...
Diamyd Medical appoints new head of Clinical Development
01 sept. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that Martina Widman, M.Sc. in Mechanical Engineering from the Royal Institute of
Technology in Stockholm and employed in...
Diamyd Medical får ny chef för klinisk utveckling
01 sept. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag att Martina
Widman, civilingenjör från KTH och anställd i Diamyd Medical sedan 2008, per
den 1 september efterträder Erika Hillborg...
Diamyd Medical’s associated company Cellaviva is appointed European distributor for StemBioSys
02 août 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that its associated company Cellaviva AB has signed an agreement regarding the
European distribution rights for a stem...
Diamyd Medicals intressebolag Cellaviva utses till europeisk återförsäljare för StemBioSys
02 août 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) meddelade idag att
Diamyd Medicals intressebolag Cellaviva AB skrivit avtal om europeiska
återförsäljningsrättigheter för en...
Diamyd Medical tecknar avtal med Janssen R&D, JDRF och University of Alabama om pågående GABA/GAD-studie
29 juil. 2016 04h39 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag att Diamyd
Medical har tecknat ett avtal med Janssen Research & Development, Juvenile
Diabetes Research Foundation (JDRF) och...
Diamyd Medical signs agreement with Janssen R&D, JDRF and UAB regarding ongoing GABA/GAD-trial
29 juil. 2016 04h39 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that it has signed an agreement with Janssen Research & Development, the
Juvenile Diabetes Research Foundation (JDRF) and...